STRONG PERFORMANCE AND INVESTMENTS FOR THE FUTURE 2020 has been a challenging year, but it is with both delight and pride I can look back on the year and the progress we have made within both our business areas. Nanologica’s strong growth continued and we reached record net sales for the Company so far, at the same time as we made large investments to be able to create value over time. We passed a large
The number of shares in Nanologica AB (publ) has changed during the month of February as a result of options from the stock option program 2018/21 being exercised. A share-based incentive program of a maximum of 483 883 options was decided by the Annual General Meeting May 31, 2018. The program expires July 1st, 2021 and the options may be exercised any time before that to a strike price of SEK 9.3. According to the
SUMMARY OF THE PERIOD FINANCIAL OVERVIEW Net revenue increased by 75 percent to TSEK 16 135 (9 227) in total, of which the fourth quarter TSEK 6 071 (2 731) The operating result for the period was TSEK -19 571 (-20 066), of which the fourth quarter TSEK -3 648 (-6 260) Loss for the period was TSEK -22 199 (-21 080), of which the fourth quarter TSEK -5 427 (-6 855) Loss per share for the period
PERIODEN I KORTHET FINANSIELL SAMMANFATTNING Nettoomsättningen ökade med 75 procent till 16 135 TSEK (9 227), varav fjärde kvartalet 6 071 TSEK (2 731) Rörelseresultatet uppgick till -19 571 TSEK (-20 066), varav fjärde kvartalet -3 648 TSEK (-6 260) Resultatet efter skatt uppgick till -22 199 TSEK (-21 080), varav fjärde kvartalet -5 427 TSEK (-6 855) Resultat per aktie var -0,93 SEK (-1,27), varav fjärde kvartalet -0,20 SEK (-0,41) Likvida medel uppgick på
